RxDoctor Payments DataLook up a doctor →

Ivan Gamboa, MD

Endocrinology, Diabetes & Metabolism · Baton Rouge, LANPI 1366739468

Payments from drug & device makers

$24,746in general payments, 2019–2025

Across 1,322 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Medtronic$2K
  • Lilly USA, LLC$2K
  • Abbott$1K
  • AstraZeneca$1K
  • Amgen$1K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk250$3,375
Medtronic(2 entities)44$2,173
Lilly USA, LLC131$1,774
Abbott67$1,467
AstraZeneca(2 entities)52$1,393
Amgen(2 entities)71$1,241
Dexcom, Inc.70$1,218
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC81$1,215
Sanofi-aventis U.S. LLC66$1,020
Xeris Pharmaceuticals, Inc.46$901
Boehringer Ingelheim55$896
Corcept Therapeutics34$868
Radius Health, Inc.30$707
Insulet Corporation23$661
AbbVie21$447
Bayer18$447
Antares Pharma, Inc.19$394
Merck27$373
Novartis22$320
IBSA Pharma Inc.17$319
Amneal Pharmaceuticals LLC20$286
BETA Bionics, Inc.12$249
Amarin Pharma, Inc.13$231
Ascendis Pharma Endocrinology Inc6$214
Nevro Corp.5$193
Mannkind Corporation6$189
BD10$183
Tolmar, Inc.9$172
Kowa Pharmaceuticals America, Inc.10$169
Recordati_rare_diseases_inc.8$157
Kyowa Kirin, Inc.7$156
Ultragenyx Pharmaceutical Inc.7$135
Neurocrine Biosciences, Inc.6$134
Sequel Med Tech, LLC5$106
Kvk-tech, Inc.10$103
Pfizer5$96
Chiesi USA, Inc.3$68
Globus Medical2$62
Shire North American Group Inc3$48
UCB, Inc.2$48
Amryt Pharma Holdings Ltd2$42
Lundbeck LLC2$41
Madrigal Pharmaceuticals2$39
Companion Medical, Inc.2$34
Cequr Corporation2$31
Clarus Therapeutics Inc.2$30
Biotronik NRO, Inc.1$29
Acerus Pharmaceuticals Corporation2$28
Endo Pharmaceuticals Inc.2$28
Genentech USA, Inc.1$26
Almatica Pharma LLC1$25
Biogen1$24
Rhythm Pharmaceuticals, Inc.1$23
Halozyme Inc1$20
Averitas Pharma Inc.1$20
Zealand Pharma US, Inc.1$20
Soleno Therapeutics, Inc.1$18
Acella Pharmaceuticals, LLC1$18
Teva Pharmaceuticals USA, Inc.1$16
Amphastar Pharmaceuticals, Inc.1$13

How this compares

$24,746 in reported general payments places this provider in the 80th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana

Medicare billing

Part B allowed, 2024
$41,835
Medicare patients
180
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →